The increasing prevalence of chronic conditions like cardiovascular disease is driving the demand for transmucosal drugs. Key factors contributing to the transmucosal drugs market's growth from ...

DelveInsight's Transmucosal Drugs Market Insights report provides the current and forecast market analysis, individual ...

Merck and a woman suing the drugmaker agreed to halt a trial over alleged injuries from the drugmaker's human papillomavirus ...

Merck (MRK) stock in focus as anti-cancer agent Welireg is approved in the EU for kidney tumor conditions, VHL disease and ...

According to Benzinga Pro, Merck & Co's peer group average for short interest as a percentage of float is 4.05%, which means the company has less short interest than most of its peers. Did you know ...

Gilead (GILD) stock won an upgrade from Deutsche Bank on HIV treatment boost, while Merck (MRK) stock received a downgrade on ...

Organon & Co. (NYSE:OGN), a global healthcare company spun off from Merck (NSE:PROR) in 2021, has established itself as a leader in women's health while expanding its presence in biosimilars and ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

Laboratory Co. of America (NYSE:LH – Free Report) had its price target increased by Piper Sandler from $240.00 to $260.00 in a report released on Monday,Benzinga reports. They currently have a neutral ...

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Merck ...

Co., Inc. (NYSE:MRK), recently acquired 15,000 shares of the company's common stock. The transaction, which took place on ...

Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of foreign exchange, ...